retifanlimab sold brand name zynyz anticancer medication used treatment merkel cell retifanlimab programmed death monoclonal approved medical use united states march retifanlimab indicated treatment adults metastatic recurrent locally advanced merkel cell us food drug administration fda evaluated safety efficacy retifanlimab based openlabel multiregional singlearm study evaluating participants metastatic recurrent locally advanced mcc received prior systemic therapy advanced fda granted application retifanlimab priority review fast track orphan drug retifanlimab international nonproprietary immune activation dostarlimab ibalizumab pharmacologyrelated article stub help wikipedia expanding ithttpsenwikipediaorgwikiretifanlimab